Hims & Hers Health (NYSE:HIMS) Price Target Increased to $23.00 by Analysts at Truist Financial

Hims & Hers Health (NYSE:HIMS) had its price objective lifted by Truist Financial from $13.00 to $23.00 in a report released on Thursday morning, Benzinga reports. They currently have a hold rating on the stock.

A number of other equities analysts have also recently commented on HIMS. TD Cowen lifted their target price on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a buy rating in a report on Thursday, July 11th. Piper Sandler upped their target price on shares of Hims & Hers Health from $16.00 to $18.00 and gave the company a neutral rating in a report on Thursday, July 11th. Jefferies Financial Group increased their target price on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a hold rating in a research note on Thursday, June 27th. Canaccord Genuity Group began coverage on Hims & Hers Health in a research report on Wednesday, April 10th. They issued a buy rating and a $20.00 price target on the stock. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on Hims & Hers Health from $14.00 to $16.00 and gave the stock a hold rating in a research report on Tuesday, May 7th. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $19.07.

Hims & Hers Health Trading Down 7.4 %

Shares of NYSE:HIMS opened at $20.37 on Thursday. Hims & Hers Health has a 12 month low of $5.65 and a 12 month high of $25.74. The company’s fifty day moving average price is $20.09 and its 200 day moving average price is $14.70.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. The business had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business’s quarterly revenue was up 45.8% on a year-over-year basis. During the same period in the previous year, the business earned ($0.05) EPS. On average, analysts anticipate that Hims & Hers Health will post 0.2 EPS for the current fiscal year.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 2,503 shares of the stock in a transaction dated Monday, April 29th. The shares were sold at an average price of $12.56, for a total value of $31,437.68. Following the completion of the transaction, the insider now directly owns 161,860 shares of the company’s stock, valued at $2,032,961.60. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, insider Patrick Harrison Carroll sold 10,000 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $13.00, for a total transaction of $130,000.00. Following the completion of the transaction, the insider now directly owns 173,880 shares in the company, valued at approximately $2,260,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Soleil Boughton sold 2,503 shares of the company’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $12.56, for a total value of $31,437.68. Following the completion of the sale, the insider now directly owns 161,860 shares in the company, valued at approximately $2,032,961.60. The disclosure for this sale can be found here. Insiders sold 981,653 shares of company stock worth $18,588,465 in the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 3.1% during the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after purchasing an additional 428,671 shares during the last quarter. FNY Investment Advisers LLC acquired a new stake in Hims & Hers Health during the fourth quarter worth approximately $48,000. Allspring Global Investments Holdings LLC grew its stake in Hims & Hers Health by 103.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 43,662 shares of the company’s stock worth $389,000 after acquiring an additional 22,170 shares during the period. Custom Index Systems LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at $132,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Hims & Hers Health by 5.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after purchasing an additional 1,561 shares during the period. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.